Seroatlas · Human Serome Atlas

BCL2

Apoptosis regulator Bcl-2

Also known as: Bcl-2, BCL2_HUMAN, PPP1R50

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P10415
Gene
BCL2
Ensembl
ENSG00000171791
Chromosome
18
Canonical length
239 aa
Protein class
Cancer-related genes, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location
Mitochondria
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene encodes an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2016]

Canonical amino-acid sequenceUniProt

239 residues, UniProt reviewed canonical sequence.

>P10415|BCL2
     1  MAHAGRTGYD NREIVMKYIH YKLSQRGYEW DAGDVGAAPP GAAPAPGIFS SQPGHTPHPA
    61  ASRDPVARTS PLQTPAAPGA AAGPALSPVP PVVHLTLRQA GDDFSRRYRR DFAEMSSQLH
   121  LTPFTARGRF ATVVEELFRD GVNWGRIVAF FEFGGVMCVE SVNREMSPLV DNIALWMTEY
   181  LNRHLHTWIQ DNGGWDAFVE LYGPSMRPLF DFSWLSLKTL LSLALVGACI TLGAYLGHK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BCL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.36
Highest tissue expression
22 nTPM

Expression across tissuesHPA

Tissue

  • thyroid gland: 22 nTPM
  • thymus: 17 nTPM
  • spleen: 17 nTPM
  • skeletal muscle: 16 nTPM
  • lymph node: 14 nTPM
  • tonsil: 14 nTPM

Single-cell type

  • pituitary stem cells: 1,811 nCPM
  • adipocytes: 1,139 nCPM
  • melanocytes: 1,004 nCPM
  • respiratory ionocytes: 902 nCPM
  • salivary ionocytes: 900 nCPM
  • schwann cells: 870 nCPM

Immune cell

  • T-reg: 8.6 nTPM
  • MAIT T-cell: 7.6 nTPM
  • memory CD4 T-cell: 6.3 nTPM
  • memory B-cell: 5.4 nTPM
  • memory CD8 T-cell: 3.4 nTPM
  • naive CD4 T-cell: 3.4 nTPM

Brain region

  • medulla oblongata: 37 nTPM
  • thalamus: 31 nTPM
  • midbrain: 30 nTPM
  • spinal cord: 30 nTPM
  • basal ganglia: 29 nTPM
  • hypothalamus: 27 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about BCL2.

Disease | ImmuneIEDB

Conditions an epitope on BCL2 was assayed in.

ReferencesPubMed · IEDB

Publications for BCL2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.71
gnomAD pLI
0.56
gnomAD missense Z
1.4
DepMap mean gene effect
-0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of BCL2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BCL2 as an antibody target. Whether an autoantibody or antibody against BCL2 could matter depends on whether native BCL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BCL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label BCL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/BCL2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...